McKesson Reports Fiscal 2017 Second-Quarter Results and Revised Fiscal 2017 Outlook

Go back to McKesson Reports Fiscal 2017 Second-Quarter Results and Revised Fiscal 2017 Outlook

Standpoint Research Upgrades McKesson (MCK) to Buy

October 28, 2016 10:29 AM EDT

Standpoint Research upgraded McKesson (NYSE: MCK) from Hold to Buy.

For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.

Shares of McKesson closed at $160.50 yesterday.

... More

Deutsche Bank Downgrades McKesson (MCK) to Hold

October 28, 2016 7:17 AM EDT

Deutsche Bank downgraded McKesson (NYSE: MCK) from Buy to Hold with a price target of $153.00 (from $196.00). Analyst George Hill expressed fears of a price war in drug wholesaling.

"MCK reported F2Q results below consensus, but it was the company's outlook and... More

Leerink Partners Downgrades McKesson (MCK) to Market Perform

October 28, 2016 7:08 AM EDT

Leerink Partners downgraded McKesson (NYSE: MCK) from Outperform to Market Perform with a price target of $160.00.

Analyst David Larsen commented, "MCK reported F2Q:17 adjusted EPS of $2.94 (-11% y/y) which was well below Leerink/Consensus of $3.10/$3.04. Management also reduced F2017 EPS... More

Baird Downgrades McKesson (MCK) to Neutral

October 28, 2016 6:49 AM EDT

Baird downgraded McKesson (NYSE: MCK) from Outperform to Neutral with a price target of $164.00 (from $220.00).

For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.

Shares of McKesson closed at $160.50 yesterday.

... More